Search

Heron Therapeutics Inc

Avatud

SektorTervishoid

0.31 -3.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.31

Max

0.32

Põhinäitajad

By Trading Economics

Sissetulek

2.6M

-5.5M

Müük

3M

38M

Aktsiakasum

-0.03

Kasumimarginaal

-14.573

Töötajad

128

EBITDA

2.1M

-5.5M

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-37M

60M

Eelmine avamishind

3.44

Eelmine sulgemishind

0.31

Uudiste sentiment

By Acuity

81%

19%

309 / 339 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. sept 2026, 23:56 UTC

Event
News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

17. sept 2026, 23:41 UTC

News
Correlated Moves

Starwood Property Trust Inc announced a quarterly dividend of $0.48 per share, with shares moving higher in after-market trading following the announcement.

17. sept 2026, 23:41 UTC

News
Correlated Moves
Macro Event

USD/HUF exchange rate is declining amid mixed macroeconomic signals, including a drop in U.S. initial jobless claims and weaker housing data.

17. sept 2026, 23:26 UTC

News

Incyte Corp's stock is trading higher in after-market hours as investors await an FDA decision on zilurgisertib, with a target date of September 26.

17. sept 2026, 23:16 UTC

News

Leonardo DRS, Inc. is higher in after-market trading following a contract with Doosan Enerbility to supply propulsion systems for South Korea's KDDX destroyer program.

17. sept 2026, 23:16 UTC

News

Modine Manufacturing announces key merger dates and terms with Gentherm, including a $1.90 special cash dividend, as shares trade higher in after-market hours.

17. sept 2026, 23:11 UTC

News

Cooper Companies shares are higher in after-market trading following insider purchases totaling $549K, despite calls for major changes from Jana Partners.

17. sept 2026, 23:11 UTC

News

Enterprise Financial Services Corp shares declined in after-market trading following an Equal Weight rating initiation by Stephens analyst Brandon Rud.

17. sept 2026, 23:11 UTC

News

Hercules Capital appointed Alfred B. Fichera to its Board of Directors, effective September 17, 2026, with stock trading modestly higher in after-market hours.

17. sept 2026, 23:06 UTC

Social Media
News

Ultragenyx Pharmaceutical Inc. gained FDA approval for Fayuvi, the first gene therapy for Sanfilippo syndrome type A, driving after-market trading higher.

17. sept 2026, 23:06 UTC

News

Coinbase Global Inc. shares are modestly lower in after-market trading as CEO Brian Armstrong declares the Clarity Act likely "dead" and explores alternative regulatory paths.

17. sept 2026, 23:06 UTC

News

Twist Bioscience Corp's stock rises after a partnership with Eli Lilly's TuneLab, with Leerink raising its price target to $160 and increased fiscal 2026 sales guidance.

17. sept 2026, 23:06 UTC

News
Correlated Moves
Macro Event

USD/SGD exchange rate is experiencing a slight decline, remaining roughly flat since Wednesday, amid mixed macroeconomic data impacting market sentiment.

17. sept 2026, 23:06 UTC

Correlated Moves
News

The USD/CZK is trading lower, reflecting routine price movement despite recent strength, with little change since Wednesday's close.

17. sept 2026, 23:01 UTC

Social Media
News

Xenon Pharmaceuticals submits a New Drug Application for azetukalner but pauses new patient enrollment in other studies, leading to a significant decline in after-hours trading.

17. sept 2026, 23:01 UTC

News
Event

Nucor Corporation's after-market shares declined following third-quarter earnings guidance of $5.55 to $5.65 per share, below the consensus estimate of $6.20.

17. sept 2026, 23:01 UTC

News

Walt Disney Co's stock is modestly higher in after-market trading following leadership changes aimed at enhancing its direct-to-consumer offerings.

17. sept 2026, 23:01 UTC

News
Correlated Moves

Rithm Capital Corp declared a quarterly dividend of $0.25 per share, with the stock advancing in after-market trading following the announcement.

17. sept 2026, 23:01 UTC

News

Campbell's Company extended the maturity date of its $1.85 billion credit agreement to April 16, 2031, and is modestly higher in after-market trading.

17. sept 2026, 22:11 UTC

News

WBD's stock is trading modestly higher in after-market hours following FCC approval of foreign funding for the Paramount merger, enhancing operational synergies.

17. sept 2026, 22:02 UTC

News

Agree Realty Corporation has priced $400 million in senior unsecured notes to enhance liquidity, with shares modestly higher in after-market trading.

17. sept 2026, 22:01 UTC

Event
News

Steel Dynamics Inc issued Q3 2026 earnings guidance of $5.34 to $5.38 per share, below the $5.60 consensus, contributing to a decline in after-market trading.

17. sept 2026, 21:31 UTC

News

BRT Apartments Corp. declared a $0.25 quarterly dividend and approved a $10 million share repurchase program, leading to gains in after-market trading.

17. sept 2026, 20:31 UTC

News

Hub Group, Inc. declined in after-market trading following a Nasdaq delisting determination due to failure to file required reports, marking its lowest point since Thursday's close.

17. sept 2026, 20:08 UTC

News

Shares of Scholar Rock Holding Corp fell modestly as the stock continues a five-session decline, despite FDA approval for its ISEMBYLD treatment.

17. sept 2026, 20:08 UTC

Social Media
News

Dell Technologies Inc's market capitalization increased by $105 billion over 11 days, with the stock advancing today amid speculation of a price target of $630.

17. sept 2026, 20:08 UTC

News
Correlated Moves
Social Media

Shares of Advanced Micro Devices advanced today on reports of planned price increases for GPUs and CPUs due to rising wafer costs from TSMC.

17. sept 2026, 20:08 UTC

Correlated Moves
News

Cloudflare Inc. shares are higher today following Bernstein SocGen's price target increase, despite pulling back from a session high earlier.

17. sept 2026, 20:08 UTC

News

Rivian's stock is trading higher as call volume reaches 27.1k contracts, indicating strong demand ahead of its earnings report on November 3rd.

17. sept 2026, 20:08 UTC

Correlated Moves
Social Media
News

Marvell Technology's shares are advancing as it expands its agreement with GlobalFoundries to enhance silicon germanium capacity amid rising demand for optical connectivity products.

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

309 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.